MyopiaNCT07229352
Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses
A study testing Novel spectacle lens design and Spectacle lenses in people with Myopia and Myopia Progression, run by SightGlass Vision, Inc. at 1 site in United States.
Trial summary
The aim of this study is evaluate and compare the mobility performance of children in daily activities while wearing standard single vision spectacle lenses and myopia control spectacle lenses. Read more about this study
- Who is it for?
- Ages 6 to 12 yearsHealthy volunteers can take part
- Conditions the study is for
- Myopia, Myopia Progression, Juvenile Myopia
- What is being tested?
- Novel spectacle lens design and Spectacle lenses
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 2 Feb 2026to 1 Jul 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 12 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- A participant is eligible for inclusion in the study if they meet the following criteria:
- Are between the ages of 6 and 12 years of age (inclusive) at the time of informed consent/assent.
- Can achieve a corrected visual acuity of 20/20 best-corrected (or equivalent logMAR).
- Have undergone a self-reported oculo-visual examination within the past two years.
- Have no active ocular disease.
- Are willing and able to adhere to instructions, study procedures, and maintain the appointment schedule.
- Have not previously worn or participated in myopia control contact lenses for more than one month and are not currently undergoing any form of myopia control treatment.
- The subject's parent(s) or legal guardian(s) must read, understand, and sign the Statement of Informed Consent and receive a fully executed copy of the form.
Who cannot join
- A participant will be excluded from the study if they meet any of the following conditions:
- Have any systemic disease that affects ocular health.
- Are currently using or have used, within the past 7 days, any systemic or topical medications that may impact ocular health.
- Are currently using or have used any topical ophthalmic agents with anti-muscarinic properties within 7 days prior to enrollment or at any point during the study. This includes, but is not limited to, atropine, scopolamine, pirenzepine, tropicamide, cyclopentolate, and homatropine.
- Have used any oral agents with anti-muscarinic properties for a chronic period (2 months or more) or short-term (within 7 days prior to enrollment). This includes, but is not limited to, gastrointestinal anti-spasmodic medications containing atropine, hyoscyamine, and dicyclomine.
- Have known developmental delays.
- Have participated in another clinical study in the last 7 days
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Midwestern University Arizona College of Optometry
Glendale, Arizona, 85308
Javier Gantes-Nunez
About this study
Official title: Mobility Performance in Daily Activities Among Children Wearing Single Vision and Myopia Control Spectacle Lenses
The aim of this study is evaluate and compare the mobility performance of children in daily activities while wearing standard single vision spectacle lenses and myopia control spectacle lenses.
- Conditions
- Myopia, Myopia Progression, Juvenile Myopia
- Being tested
- Novel spectacle lens design, Spectacle lenses
- Medical subject headings
- Myopia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Novel spectacle lens designDevice
Use of lenses to correct myopia and may reduce the rate of progression of juvenile myopia
Spectacle lensesDevice
Use of lenses to correct myopia and may reduce the rate of progression of juvenile myopia
| Study group | Role | What they receive |
|---|---|---|
| SightGlass Vision Test Arm 1 | Experimental | Single vision, impact-resistant spectacle lenses Receives: Device: Novel spectacle lens design |
| Control Arm | Active comparator | Single vision, impact-resistant spectacle lenses Receives: Device: Spectacle lenses |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reaction time: the time elapsed between the appearance or activation of a visual stimulus and the initiation of the participant's physical response
Measured: 2 months
Movement time: the time taken to complete the motor response after it has been initiated.
Measured: 2 months
Response accuracy: the correctness of the participant's response to each visual stimulus, measured by the number or percentage of correctly identified or responded-to stimuli.
Measured: 2 months
Secondary outcomes (1)
Gait cycle events, such as initial foot contact with the ground and toe-off. It will be used to assess whether the type of eyewear affects natural gait patterns or mobility during peripheral vision tasks.
Measured: 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Nov 2025
- Study start2 Feb 2026
- Primary completion31 Dec 2027 (estimated)
- Study completion1 Jul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MyopiaStudies of the same condition, open and under way.
- More trials run by SightGlass Vision, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- SightGlass Vision, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07229352
- Sponsor's protocol ID
- CPRO-2507-001
- Status last verified
- Nov 2026
- First submitted
- 12 Nov 2025
- Last updated
- 5 Nov 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mobility Performance in Daily Activities Among Children Wearing Single Vision and Myopia Control Spectacle Lenses
- ClinicalTrials.gov ID
- NCT07229352
- Acronym / sponsor ID
- CPRO-2507-001
- Conditions
- Myopia, Myopia Progression, Juvenile Myopia
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- SightGlass Vision, Inc.Industry (pharma, biotech, devices)
- Study start
- 2 Feb 2026 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 1 Jul 2028 (estimated)
- First posted
- 17 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is evaluate and compare the mobility performance of children in daily activities while wearing standard single vision spectacle lenses and myopia control spectacle lenses.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| SightGlass Vision Test Arm 1 | Experimental | Device: Novel spectacle lens designSingle vision, impact-resistant spectacle lenses |
| Control Arm | Active comparator | Device: Spectacle lensesSingle vision, impact-resistant spectacle lenses |
Who may qualify
- Ages
- 6 to 12 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (8 listed)
- Are between the ages of 6 and 12 years of age (inclusive) at the time of informed consent/assent.
- Can achieve a corrected visual acuity of 20/20 best-corrected (or equivalent logMAR).
- Have undergone a self-reported oculo-visual examination within the past two years.
- Have no active ocular disease.
- Are willing and able to adhere to instructions, study procedures, and maintain the appointment schedule.
Key exclusion criteria (7 listed)
- A participant will be excluded from the study if they meet any of the following conditions:
- Have any systemic disease that affects ocular health.
- Are currently using or have used, within the past 7 days, any systemic or topical medications that may impact ocular health.
- Are currently using or have used any topical ophthalmic agents with anti-muscarinic properties within 7 days prior to enrollment or at any point during the study. This includes, but is not limited to, atropine, scopolamine, pirenzepine, tropicamide, cyclopentolate, and homatropine.
- Have used any oral agents with anti-muscarinic properties for a chronic period (2 months or more) or short-term (within 7 days prior to enrollment). This includes, but is not limited to, gastrointestinal anti-spasmodic medications containing atropine, hyoscyamine, and dicyclomine.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Novel spectacle lens designUse of lenses to correct myopia and may reduce the rate of progression of juvenile myopia | Device | SightGlass Vision Test Arm 1 |
| Spectacle lensesUse of lenses to correct myopia and may reduce the rate of progression of juvenile myopia | Device | Control Arm |
Primary outcome
Reaction time: the time elapsed between the appearance or activation of a visual stimulus and the initiation of the participant's physical response
Time frame: 2 months
Movement time: the time taken to complete the motor response after it has been initiated.
Time frame: 2 months
Response accuracy: the correctness of the participant's response to each visual stimulus, measured by the number or percentage of correctly identified or responded-to stimuli.
Time frame: 2 months
1 secondary outcome
Gait cycle events, such as initial foot contact with the ground and toe-off. It will be used to assess whether the type of eyewear affects natural gait patterns or mobility during peripheral vision tasks.
Time frame: 2 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2026.
Related trials for Myopia
Recruiting
Managing Premyopia in Chinese Children Using Artificial Intelligence Assisted Defocus Incorporated Multiple Segments Based Spectacle Lens: a Randomized Controlled Clinical Trial
Pre-myopia, Myopia
Not yet recruiting
BRIGHT-LIGHT: Studying Red Light Therapy for Severe Short-Sightedness or Short-Sightedness That Worsens Despite Standard Treatment
Myopia, Myopia Progressing
Active, not recruiting
Effect of IOP Lowering on Progressive HM
High Myopia, Intraocular Pressure
Recruiting
Evaluation of a New Laser Refractive Vision Correction Using the TENEO™ 317 Model 2
Hyperopia and Myopia
Not yet recruiting
Clinical Performance and Outcomes After Toric Lens Transition
Astigmatism
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Novel spectacle lens design and Spectacle lenses in people with Myopia and Myopia Progression, run by SightGlass Vision, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jennifer Hill (6783614877, jhill@sightglassvision.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reaction time: the time elapsed between the appearance or activation of a visual stimulus and the initiation of the participant's physical response (time frame: 2 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026; AzTrials last refreshed its copy on 7 Nov 2026.